VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

This trial is testing a new drug combination — VX15/2503 (an experimental antibody) combined with either ipilimumab or nivolumab (both immune-boosting drugs) — given before surgery to patients with head and neck cancer, to see if this approach can shrink tumors and improve outcomes. **You may be eligible if...** - You have been diagnosed with head and neck squamous cell carcinoma (a type of cancer in the mouth, throat, or related areas), at stages I through IVA - Your cancer is confirmed to be removable by surgery - You have not received any prior treatment for this head and neck cancer - You are well enough to carry out daily activities (ECOG 0 or 1) - Your blood counts and organ function meet minimum requirements **You may NOT be eligible if...** - You have poor vein access for receiving the study drug - You have nasopharynx cancer or cancer of unknown primary origin - You have an active autoimmune disease requiring immune-suppressing treatment - You have had a prior stem cell transplant - You are pregnant or breastfeeding - You are currently receiving other immunosuppressive therapy Talk to your doctor to see if this trial is right for you.